Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
MP
MapLight Therapeutics, Inc. Common Stock
MPLT
Mkt Cap
$427.7M
Volume
315.68K
Next Earnings
December 3rd
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
MP
MPLT
MP
MapLight Therapeutics, Inc. Common Stock
MPLT
News
·
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold?
Mkt Cap
$427.9M
Volume
315.68K
Next Earnings
December 3rd
Chart
Financials
Earnings
News
About
Insider
Filings
MapLight's CFO Just Sold 36,000 Shares for $1 Million. Is It a Buy, Sell, or Hold?
MapLight Therapeutics' CFO Setia Vishwas sold 36,371 shares worth approximately $1.02 million in May 2026 through a pre-arranged Rule 10b5-1 trading plan. The sale reduced his direct holdings by 9.3%, though he retains 356,256 shares. The article notes this shouldn't be interpreted as a lack of confidence since it was part of a predetermined trading plan. MapLight, a clinical-stage biotech company focused on CNS disorders, has seen its stock gain 70.8% over the past year but continues to report deepening losses as it advances its pipeline.
The Motley Fool · May 15, 2026
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
MapLight Therapeutics announced that its Phase 2 ZEPHYR trial for ML-007C-MA (schizophrenia treatment) and Phase 2 IRIS trial for ML-004 (autism spectrum disorder) are progressing ahead of schedule, with topline results now expected in Q3 2026. The company cited accelerated enrollment pace and disciplined execution as drivers of the timeline acceleration.
GlobeNewswire Inc. · Jan 9, 2026
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
MapLight Therapeutics completed its initial public offering of 16,962,500 shares at $17.00 per share, raising $296.3 million. The company is a clinical-stage biopharmaceutical firm focused on central nervous system disorders, with a lead product candidate ML-007C-MA for schizophrenia and Alzheimer's disease psychosis.
Benzinga · Oct 29, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
MP
MPLT
MapLight Therapeutics, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
MPLT
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any MPLT yet.
Related Tickers
Earnings